An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment
Phase of Trial: Phase I
Latest Information Update: 06 Jul 2018
At a glance
- Drugs Abivertinib-maleate (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 28 Jun 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 28 Jun 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jul 2018.
- 29 Sep 2017 Planned number of patients changed from 6 to 7.